Wednesday, September 16, 2026
23.5 C
Bengaluru

Simon Rosof has been appointed Head of Asia Pacific for Bayer Pharmaceuticals

Simon Rosof has been appointed Head of Asia Pacific for Bayer Pharmaceuticals, effective July 1, 2026. Based in Singapore, he will additionally serve as Country Division Head for the ASEAN cluster, managing business strategy and operational performance across Southeast Asia.

Asia Pacific, home to over 2.6 billion people, represents one of the most dynamic healthcare regions globally. The growing demand for innovative treatments and evolving patient needs make this a critical market for Bayer’s strategic expansion. In his new role, Rosof will focus on driving growth, strengthening healthcare partnerships, and expanding patient access to innovative medicines throughout the region.

With more than two decades in the pharmaceutical industry, Rosof brings deep expertise in commercial strategy, portfolio management, and general leadership. He previously held senior leadership roles at Bayer and Bristol Myers Squibb, including Senior Vice President and Head of Product & Pipeline in the U.S., where he oversaw commercialization in Oncology, Cardiovascular & Renal, and Women’s Healthcare. His experience spans both marketed products and pipeline assets, along with shaping corporate pharmaceutical strategy at a global level .

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Medical Reps—Lessons From The West: The Old Model is Dead

The Core Conclusion The Western pharma industry is not simply...

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

How wearables, diagnostics, AI and continuous monitoring are moving...

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

RPG Active Pharma’s agreement to acquire the API and...

Pharmacy of the World Pricing Paradox

India occupies an extraordinary position in global pharmaceuticals. It...

Topics

Medical Reps—Lessons From The West: The Old Model is Dead

The Core Conclusion The Western pharma industry is not simply...

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

How wearables, diagnostics, AI and continuous monitoring are moving...

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

RPG Active Pharma’s agreement to acquire the API and...

Pharmacy of the World Pricing Paradox

India occupies an extraordinary position in global pharmaceuticals. It...

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

India has two very different pharmaceutical regulators living inside...

MedicinMan Pharma Pulse: August 2026

🚀 The Mega-Merger That Wasn't Early August saw the...

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...
spot_img

Related Articles

spot_imgspot_img